WHWK Q2 2026: $190M cash balance extends runway to 2H 2028, HWK-206 Phase 1 initiation the next milestone
In focus for clinical oncology watchers Thursday: Whitehawk Therapeutics (Nasdaq: WHWK) posted a second-quarter 2026 net loss of $16.6 million and ended the period with $190.0 million in cash, cash equivalents and short-term investments. That balance, up from $145.7 million at December 31, 2025, is anticipated to fund operations into the second half of 2028. The next confirmable date on the tape is the Phase 1 trial initiation for HWK-206, planned for Q3 2026.
Key takeaways
- Whitehawk Therapeutics (Nasdaq: WHWK) reported a Q2 2026 net loss of $16.6 million, down from $52.6 million in Q2 2025.
- The company ended the quarter with $190.0 million in cash, cash equivalents and short-term investments, up from $145.7 million at December 31, 2025, funding operations into the second half of 2028.
- The next near-term catalyst is the Phase 1 trial initiation for HWK-206, targeting small-cell lung cancer and neuroendocrine tumors, planned for Q3 2026.
- Two Phase 1 studies (HWK-007 and HWK-016) are actively enrolling, with initial readouts from each expected in the first half of 2027.
- The cash position reflects a May 2026 private placement, an $87.5 million financing that included investors such as Avoro Capital, QVT, and members of the Whitehawk executive team.
In focus for clinical oncology watchers Thursday: Whitehawk Therapeutics (Nasdaq: WHWK) posted a second-quarter 2026 net loss of $16.6 million and ended the period with $190.0 million in cash, cash equivalents and short-term investments. That balance, up from $145.7 million at December 31, 2025, is anticipated to fund operations into the second half of 2028. The next confirmable date on the tape is the Phase 1 trial initiation for HWK-206, planned for Q3 2026.
The numbers behind the print
Research and development expenses came in at $12.9 million for the quarter ended June 30, 2026, against $48.8 million in the year-prior period. The prior-year figure included a $38.0 million up-front license fee paid to WuXi Biologics, which drove most of that gap. Net loss compressed from $52.6 million in Q2 2025 to $16.6 million this quarter.
The cash position reflects the May 2026 private placement, an $87.5 million financing that included Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus, and members of the Whitehawk executive team.
Pipeline status and the Q3 catalyst
Two Phase 1 studies are actively enrolling. HWK-007 is being evaluated in patients with non-squamous, EGFR wild-type non-small cell lung cancer, platinum-resistant ovarian cancer, and endometrial cancer (NCT07444814). HWK-016 is enrolling patients with advanced ovarian and endometrial cancers (NCT07470853). Both programs had their study designs presented at the American Society of Clinical Oncology 2026 annual meeting. Initial readouts from each are expected in the first half of 2027.
HWK-206, targeted at small-cell lung cancer and neuroendocrine tumors, is on track for Phase 1 initiation in Q3 2026. That start date is the near-term catalyst to watch for WHWK shares.
Platform deals and what to watch
Beyond the active trials, Whitehawk entered an option agreement with Hangzhou DAC covering the CPT113 linker-payload technology for use in up to five additional ADC programs. Under the terms, Whitehawk selects targets and sources antibodies while retaining global rights and full program control. A separate global collaboration with Biocytogen grants access to up to five bispecific antibodies from Biocytogen's RenLite platform, which Whitehawk will evaluate alongside its own ADC technology. The company is targeting multiple new investigational new drug applications over the next 12 to 24 months.
For the setup: the 2H 2028 cash runway removes near-term financing pressure from the picture. The tape's next hard signal is HWK-206 Phase 1 enrollment confirmation in Q3 2026, with the 1H 2027 window for initial Phase 1 data from HWK-007 and HWK-016 following after that.
Related reading
Filed by the newsroom of MarketPR on August 6, 2026. Source: sec.gov. Indicative figures are not investment advice.